Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cancer

A 52-Year-Old Lupus Paper Remains Important Today

Ruth Jessen Hickman, MD  |  December 14, 2020

Over 50 years ago, an article appeared in The New England Journal of Medicine: “Immunologic Factors and Clinical Activity in Systemic Lupus Erythema­tosus.”1 Written by a young postdoctoral fellow, Peter H. Schur, MD, and colleagues, the article synthesized important work in the field at the time. What follows is a discussion of the historical context…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:Dr. Peter SchurLost & Found

Long-Term Safety of Baricitinib for RA

Michele B. Kaufman, PharmD, BCGP  |  December 14, 2020

Baricitinib appears to be a safe long-term treatment for RA patients, according to a recent analysis of patients with drug exposure up to eight years.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2020baricitinibJAK inhibitorRheumatoid Arthritis (RA)

Medicare’s Most Favored Nation Is My Least Favorite Notion!

Angus B. Worthing, MD  |  December 8, 2020

In case you missed it, on Nov. 20, the  Centers for Medicare & Medicaid Services (CMS), a department within the U.S. Department of Health and Human Services, announced that it will overhaul the payment system for Medicare Part B (i.e., infusion) drugs on Jan. 1, 2021. The plan is called the Most Favored Nation (MFN)…

Filed under:Legislation & AdvocacyOpinionProfessional TopicsSpeak Out Rheum Tagged with:MedicareMost Favored Nation

ACR Convergence graphic

Check It Out: Understanding Immune-Related Adverse Events from Immune Checkpoint Inhibitors

Jason Liebowitz, MD, FACR  |  December 4, 2020

Immune checkpoint inhibitors effectively treat malignancy in ways that were not possible just a few years ago, but immune-related adverse events are a potential side effect.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2020immune checkpoint inhibitor (ICI)Immune checkpoint inhibitorsimmunotherapy

Osteoporosis Experts Discuss Bisphosphonate Holidays

Susan Bernstein  |  November 24, 2020

ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday?…

Filed under:ACR ConvergenceConditionsMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:ACR Convergence 2020bisphosphonatesbone mineral density (BMD)drug holidayFracturesOsteoporosis

Top Research in Lupus Presented at ACR Convergence 2020

David S. Pisetsky, MD, PhD  |  November 20, 2020

ACR CONVERGENCE 2020—Held Nov. 5–9, the ACR’s first fully virtual annual meeting is a wrap, but that doesn’t mean it’s too late to catch the highlights. Dozens of research abstracts on various aspects of lupus were presented during the fully virtual event, and David S. Pisetsky, MD, PhD, professor of medicine and immunology at Duke…

Filed under:ACR ConvergenceConditionsMeeting ReportsResearch RheumSystemic Lupus Erythematosus Tagged with:ACR Convergence 2020ACR Convergence 2020 - SLEDavid S. PisetskyLupusPisetsky

Study: DPP4 Inhibitors Yield Promise for Systemic Sclerosis Treatment

Ruth Jessen Hickman, MD  |  November 12, 2020

A recent paper in Arthritis & Rheumatology opens up the possibility of a new research avenue to treat systemic sclerosis: dipeptidyl peptidase 4 (DPP4) inhibitors, a previously approved therapy for type 2 diabetes.1 Work in mouse models and on skin samples from systemic sclerosis patients suggests these drugs pose a promising area of future translational…

Filed under:ConditionsOther Rheumatic ConditionsResearch Rheum Tagged with:DPP4 inhibitorsystemic sclerosis (SSc)

What’s the Role of Epstein-Barr Virus Reactivation in Lupus Development?

Larry Beresford   |  November 12, 2020

A strong association between Epstein-Barr virus (EBV) infections and systemic lupus erythematosus (SLE) has been known since the 1970s. Although the etiology of SLE is not fully established, multiple genetic factors and polymorphisms in genes involved in the immune system have been implicated, with environmental factors also contributing to the development of this complex condition….

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:Epstein-Barr virus (EBV)

The 2020 ACR Awards of Distinction & Masters Class

Linda Childers  |  November 12, 2020

Presidential Gold Medal The highest award the ACR can bestow, the Presidential Gold Medal is awarded in recognition of outstanding achievements in rheumatology over an entire career. This year’s award went to James O’Dell, MD, the Stokes-Shackleford Professor of Internal Medicine, vice chair of internal medicine and chief of the Division of Rheumatology at the…

Filed under:Awards Tagged with:ACR Convergence 2020Ciarán M. DuffyDr. Abby AbelsonDr. Ami Aalok ShahDr. Andras PerlDr. Angela TincaniDr. Bernardo A. Pons-EstelDr. Brian F. MandellDr. Carlos J. LozadaDr. Daniel SolomonDr. Edward K.L. ChanDr. Emily IsaacsDr. James O’DellDr. James R. SeiboldDr. James WitterDr. Joanne M. JordanDr. Kara PetersenDr. Kathleen M. O’NeilDr. Leonard H. SigalDr. M. Virginia PascualDr. Martin Jan BergmanDr. Michael B. BrennerDr. Nancy E. LaneDr. Norman T. IlowiteDr. Pamela WeissDr. Pierre MiossecDr. Robert W. WarrenDr. Sheldon SolomonDr. Stuart Kassan

Dr. Fauci Talks COVID-19 with the ACR

Susan Bernstein  |  November 10, 2020

ACR CONVERGENCE 2020—At the ACR’s fully virtual annual meeting on Saturday, Nov. 7, Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID) since 1984, delivered a special lecture on COVID-19, from virology to therapy to vaccine development. Novel Coronavirus, Familiar Vectors When Chinese physicians first reported infections by what…

Filed under:ACR ConvergenceMeeting Reports Tagged with:ACR Convergence 2020Anthony S. FauciCOVID-19

  • « Previous Page
  • 1
  • …
  • 20
  • 21
  • 22
  • 23
  • 24
  • …
  • 84
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences